Tuesday, 13 November, 2012
Systemic TNF Gene Therapy Synergizes With Liposomal Doxorubicine in the Treatment of Metastatic Cancer
B. Su, A. Cengizeroglu, K. Farkasova, J. Viola, M. Anton, J. Ellwart, R. Haase, E. Wagner, and M. Ogris -
Molecular Therapy, doi: 10.1038/mt.2012.229, published online: 13 November 2012
Tumor necrosis factor alpha (TNF) is a potent antitumoral cytokine, either killing tumor cells directly or affecting the tumor vasculature leading to enhanced accumulation of macromolecular drugs. Due to dose limiting side effects systemic administration of TNF protein at therapeutically active doses is precluded. With gene vectors, tumor restricted TNF expression can be achieved and in principle synergize with chemotherapy. Synthetic gene carriers based on polyamines were intravenously injected, which either passively accumulate within the tumor or specifically target the epidermal growth factor receptor. A single intravenous injection of TNF gene vector promoted accumulation of liposomal doxorubicine (Doxil) in murine neuroblastoma and human hepatoma by enhancing tumor endothelium permeability. The expression of transgenic TNF was restricted to tumor tissue. Three treatment cycles with TNF gene vectors and Doxil significantly delayed tumor growth in subcutaneous murine Neuro2A neuroblastoma. Also tumors re-growing after initial treatment were successfully treated in a fourth cycle pointing at the absence of resistance mechanisms. Systemic Neuro2A metastases or human LS174T colon carcinoma metastases in liver were also successfully treated with this combined approach. In conclusion, this schedule opens the possibility for the efficient treatment of tumors metastases otherwise not accessible for macromolecular drug carriers.